Trial Details

ACTIVE_NOT_RECRUITING
Basic Information
Clinical ID c507
Identifier NCT05158517
Trial Title VeDOlizumab PERsistence in IBD Patients After Switching From Intravenous to Subcutaneous Administration : a Real-life Multicenter Study (DOPER)
Trial URL Visit Original Page
Study Information
Study Results

NO

Conditions Inflammatory Bowel Diseases
Interventions DRUG: Subcutaneous vedolizumab
Participant Information
Sponsor Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
City Grenoble
Country/Region France
Enrollment Criteria
Sex Requirement ALL
Age Requirement ADULT, OLDER_ADULT
Study Design
Study Type OBSERVATIONAL
Phase -
Time Information
Start Date 2022-03-20
Primary Completion Date 2024-03-31
Completion Date 2025-03-20